Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Chase Pharmaceuticals Corporation patents


Recent patent applications related to Chase Pharmaceuticals Corporation. Chase Pharmaceuticals Corporation is listed as an Agent/Assignee. Note: Chase Pharmaceuticals Corporation may have other listings under different names/spellings. We're not affiliated with Chase Pharmaceuticals Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Chase Pharmaceuticals Corporation-related inventors


Memantine combinations and use

A pharmaceutical combination of memantine and a non-anticholinergic antiemetic agent for the treatment of hypocholinergic disorders in further combination with high doses of donepezil and with solifenacin, and kits comprising said combination. A pharmaceutical combination of memantine and solifenacin for the treatment of hypocholinergic disorders, including alzheimer type dementia, in further combination with high doses of donepezil, and kits comprising said combination.. ... Chase Pharmaceuticals Corporation

Oxybutynin-xanomeline transdermal therapeutic system combinations

Transdermal therapeutic system and method of using the same for safely treating hypocholinergic disorders of the central nervous system such as alzheimer type dementia. The transdermal therapeutic system comprises oxybutynin in combination with a cholinergic receptor agonist (cra) such as xanomeline.. ... Chase Pharmaceuticals Corporation

Peripheral-anticholinergic muscarinic agonist combination

A combination of a non-selective, peripheral anticholinergic agent, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and method of using the same for the treatment of hypocholinergic disorders of the central nervous system. The combination of the present invention allows for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. ... Chase Pharmaceuticals Corporation

Oxybutynin transdermal therapeutic system muscarinic agonist combination

Pharmaceutical compositions and combinations containing a muscarinic receptor antagonist, such as oxybutynin in a transdermal therapeutic system, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and methods of using the same for treatment of hypocholinergic disorders of the central nervous system such as alzheimer type dementia. The respective pharmaceutical compositions and combinations of the present invention allow for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. ... Chase Pharmaceuticals Corporation

Anticholinergic neuroprotective composition and methods

The present invention relates to a pharmaceutical composition comprising propiverine, trospium or glycopyrrolate; and a non-anticholinergic antiemetic agent. It is also related to a pharmaceutical composition comprising a high dose of solifenacin or a pharmaceutically acceptable salts thereof; and a non-anticholinergic antiemetic agent. ... Chase Pharmaceuticals Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Chase Pharmaceuticals Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Chase Pharmaceuticals Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###